

1 **FIRST PAGE OF THE MANUSCRIPT**

2
3
4 **Title**

5 Accuracy of peak nasal flow to determine nasal obstruction in patients with allergic
6 rhinitis

7
8
9 **Running title:**

10 Peak nasal flow in allergic rhinitis

11
12
13 **Authors**

14 Gardênia Maria Martins de Oliveira¹, Marco Aurélio de Valois Correia Júnior^{2,3},
15 Emilia Chagas Costa³, Georgia Veras³, José Ângelo Rizzo³, Steve Hunter⁴, Nádia
16 Gaua⁴, Emanuel Sávio Cavalcanti Sarinho³

17
18
19 **Affiliation(s)**

20 1 – Professor of Physiotherapy, Centro Universitário Leão Sampaio. Department
21 Cardio-Respiratory Physiotherapy. Juazeiro do Norte-CE Brazil.

22 2- Post-Graduation Program in Herbiatrics and Physical education Universidade de
23 Pernambuco, Brazil.

24 3- Universidade Federal de Pernambuco-Recife, Brazil and Center for Allergy and
25 clinical immunology research at clinical hospital.

26 4- Sport and Exercise Science Research Centre, School of Applied Sciences, London
27 South Bank University, London, United Kingdom

28
29
30 **Type of Article**

31 Categorize your article in one of the following types: *Original Article*

32
33 **Corresponding author**

34 Marco Aurélio de Valois Correia Junior. Mailing address: Luiz Guimarães street, 411,
35 301-a. Poço da Panela, Recife, Pernambuco, Brazil. Zip code: 52061-160 | telephone
36 number +5581992520056, Fax number 3633-4604. Mail adress:
37 marcovalois@gmail.com.

48 **Abstract**

49 **Objective:** The aim of this study was to further investigate the ability of Peak Nasal
50 Inspiratory Flow (PNIF) and Nasal Expiratory Flow Peak (PNEF) measures to predict
51 symptoms of nasal obstruction. **Methods:** This is a cross-sectional study, carried out
52 in 131 individuals (64 with symptomatic allergic rhinitis and 67 asymptomatic) aged
53 between 16 and 50 years. **Results:** PNIF and PNEF were higher among non-rhinitis.
54 In the curve analysis (receiver operating characteristic), the value of 115 for the PNIF
55 with a sensitivity of 98.4% and specificity of 87.5% (AUC = 0.99, $p < 0.001$) and 165
56 in PNEF with a sensitivity of 65.7% and specificity of 85.1% (AUC = 0.92, $p < 0.001$)
57 was found. **Conclusions:** PNIF and PNEF values were lower in patients with AR
58 when compared to asymptomatic. Our findings present reference values of PNIF and
59 PNEF measures in the evaluation of nasal obstruction symptoms and reinforce the
60 importance to complement the more refined assessment of patients' symptoms. PNEF
61 can be a valuable tool in screening patients and to complement the PNIF
62 measurement.

63

64 **Key words**

65 Diagnostic techniques, Nasal Obstruction , Respiratory system, Rhinitis.

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81 **MAIN BODY OF MANUSCRIPT FOR ORIGINAL ARTICLES**

82

83 **Introduction**

84

85 Nasal obstruction is a frequent complaint in patients with allergic
86 rhinitis(AR)¹⁻⁴. Studies have shown that this symptom has a significant impact on
87 patients' quality of life, work productivity and sleep quality¹⁻⁴. Patients with persistent
88 and more intense forms of AR even in asymptomatic phases may experience constant
89 mucosal inflammation and chronic nasal obstruction resulting from mucosal
90 inflammation and mucus secretion¹.

91 In clinical practice nasal obstruction is difficult to quantify². Initial
92 investigations are usually performed based on patients' subjective perception³.
93 However, subjective perception of obstruction involves complex mechanisms and
94 some authors²⁻⁵ argue that in addition to patient impression, the association of
95 objective measures may be recommended to complement the assessment.

96 Peak nasal inspiratory flow(PNIF) and peak nasal expiratory flow(PNEF) are
97 techniques that have been proposed as an objective method to help in understanding
98 nasal obstruction. The PNIF was shown to have a good accuracy⁶⁻⁸, however we did
99 not find precise diagnostic parameters for the PNEF^{4,9}. The main advantage of this
100 objective technique is the fact that it is a low-cost, non-invasive, easy-to-perform
101 method that can be performed in multiple settings, such as clinics, hospitals, and the
102 individual's own home^{6,7}.

103 The increasing use of objective methods in research has raised questions about
104 the value that these measures add to clinical evaluation⁶⁻¹⁰. This study was conducted
105 to: (i) further investigate the contribution of objective methods to clinical practice in
106 the evaluation of nasal patency, notably on PNIF and PNEF measurements in patients
107 with rhinitis and without allergic rhinitis and (ii) assess the ability of these measures
108 to predict the symptoms of obstruction, including in patients having difficulty in
109 perceiving their symptoms, to help as a complementary measure in the diagnosis.

110

111

112

113

114

115 **Materials and methods**

116 *Study design, population and ethical procedures.*

117

118 This is a cross-sectional clinical study, conducted at the Allergology and
119 Immunology Service of the Clinical Hospital of the Federal University of
120 Pernambuco, Recife, Pernambuco, Brazil. Volunteers were the groups of patients with
121 allergic rhinitis, screened by the regular flow of care in allergy and immunology
122 clinics, otorhinology and allergy of the institution and the control group was
123 individuals without diagnosis of AR and no respiratory complaints.

124 The comparison group was recruited from a university environment and consisted of
125 people with no clinical diagnosis of allergic rhinitis, no complaints of nasal
126 symptoms, and especially no history of nasal obstruction, confirmed by a clinical
127 symptom score adapted by Gomes et al¹³. Inclusion criteria for the control group
128 were: a final score value of zero and the visual analog scale for nasal
129 obstruction(VAS), with its final value also being zero. The study was approved by the
130 institution's Ethics Committee(nº 063/11). All parents or guardians and the
131 adolescents signed terms of informed consent as requested by the Brazilian regulatory
132 agency.

133 *Inclusion and exclusion criteria*

134 Patients of both sexes, aged 16 to 50 years, whose diagnosis of persistent
135 allergic rhinitis were included¹¹. Those with diagnosed asthma or history suggestive
136 of asthma who had a positive response to any of the following data in the clinical
137 history were excluded: previous wheezing crisis, tiredness, recurrent wheezing after
138 physical activity without investigation, dry night cough for no apparent reason or
139 other respiratory diseases that compromise pulmonary or nasal function. Those who
140 were on regular medication for nasal symptoms including: topical corticosteroids and
141 systemic vasoconstrictors, antihistamines at the time of the study, or who had used
142 them for four weeks prior to the study. Those who used nasal decongestants in the last
143 48 hours, patients with endoscopic findings of marked septum deviation and signs
144 suggestive of concomitant acute infectious sinusitis. Smokers, asthmatics, or
145 individuals with upper respiratory tract infection at the time or 15 days before data
146 collection were also excluded. Cognitive level alteration that compromised the
147 technique was also a reason for exclusion.

148 *Instruments and data collection*

149 *Definition of clinical diagnosis*

150

151 The clinical diagnosis of AR was established by a specialist physician based
152 on patient history, physical examination and allergic skin test for aeroallergens.
153 Persistent rhinitis was classified by the same specialist according to modified
154 ARIA¹²(Allergic Rhinitis and its Impact on Asthma) criteria based on the presence of
155 one or more of the six nasal signs or symptoms that included: nasal congestion,
156 sneezing, rhinorrhea, pruritus, oropharynx, nasal and ocular pruritus for more than
157 four days a week or more than four weeks before admission. All patients had positive
158 aeroallergen pick-tests.

159 *Clinical evaluations*

160 Patients from both rhinitis and non-rhinitis groups underwent subjective
161 evaluation (visual analog scale and clinical score) and objective evaluations of the
162 PNIF and PNEF by independent examiners.

163 Patients with AR were referred to one of the researchers after consultation
164 with a specialist, prior to any prescribed drug intervention. Initially they were asked
165 about the perception of nasal obstruction using the VAS presented in a color grading,
166 taking as reference the light blue color, at the far right of the scale that corresponded
167 to the absence of nasal obstruction and at the far left, represented by the red color that
168 corresponded to the nose completely blocked. Subsequently, they marked a point on
169 the scale that seemed to them more corresponding to their nasal obstruction state. The
170 color grading presented to the patients was visualized by the researcher on a scale
171 numbered from 0 to 10, graduated in mm and after the patient registration the
172 corresponding point was recorded by the researcher. To perform the appointment it
173 was necessary that the patients had no doubts about the appointment.

174 The clinical score of nasal symptoms, adapted by Gomes et al⁸., was used to
175 evaluate the intensity of rhinitis through nasal symptoms that included: nasal
176 congestion, sneezing, rhinorrhea, oropharyngeal pruritus, nasal and ocular pruritus.
177 We used a scale from zero to 3 points, where zero indicated absence of symptoms, 1
178 mild symptom point, well tolerated, does not interfere with sleep or daily activities, 2
179 well defined symptom points, uncomfortable, interfering only with activities that
180 require greater concentration, but does not interfere with the patient's routine, 3
181 points- Intense symptom, very uncomfortable, poorly tolerated, making it difficult to

182 sleep and activities daily activities. The total score ranged from 0 to 18 points
183 allowing AR to be classified as mild (1-6 points), moderate (7-12 points), or severe
184 (13-18 points) ^{8,11}. The comparison group performed the same subjective measures as
185 the criterion for inclusion in the study with the final VAS result and the nasal
186 symptom score equal to zero.

187 *Evaluation of Objective Measures*

188 Patients with allergic rhinitis were asked to perform nasal hygiene to eliminate
189 secretion prior to verification of the PNIF and PNEF. The PNIF was measured by the
190 nasal inspiratory peak flow meter (In-Check Nasal Clement Clarke, England), with
191 the patient sitting comfortably wearing a face mask that was held by one of the
192 researchers' hands on the patient's face, with a necessary pressure to prevent air
193 leakage. Patients were instructed to perform maximal inspiratory effort through the
194 nose with the lips closed. The maneuver was repeated three times, and the largest of
195 the three measurements was recorded, with a variation up to 10%.

196 PNEF measurements were obtained using the peak expiratory flow meter
197 (Assess peak flow meter respironics, New Jersey) where a face mask was fitted
198 through a universal connector. The patient was seated in a comfortable position, with
199 the mask fixed by the hand of one of the researchers on the face, with a pressure
200 necessary to prevent leakage or air leakage. The patients were instructed to perform
201 maximal expiration through the nose with their lips closed after maximum inspiration
202 from the residual volume. Three measurements were taken in a row, the largest one
203 being considered, considering a variation between them of up to 10%.

204 *Statistical analysis*

205 Data were processed and analyzed using the Statistical Package for the Social
206 Sciences (SPSS, version 20.0). The Kolmogorov-Smirnov test was applied to test the
207 normality assumption. Mean and SD were used to present continuous variables, while
208 categorical data were presented using absolute and relative frequencies. Bilateral
209 values of p were calculated, and the significance level adopted was 5%. T test was
210 used to evaluate the comparison between the means in the different groups

211 To assess the cutoff point of PNIF and PNEF, a ROC curve was plotted and
212 the area under the curve was calculated. From the value found in PNIF and PNEF we
213 calculated the positive predictive value, negative predictive value, positive likelihood
214 ratio and negative likelihood ratio.

215

216 **Results**

217

218 A total of 131 individuals (69.5% men) participated in the study, of which 75
219 (57.2%, Control group. Among the 64 subjects with rhinitis, most had moderate
220 rhinitis(65.6%). (Table 1).

221 Peak inspiratory flow and Peak expiratory flow were higher among non-
222 rhinitis, even when separated by gender (Table 2). In non-rhinitic patients, men had
223 higher peak flows.

224 Figure 1 shows the analysis of the ROC curve for the PNIF (sensitivity of
225 98,4% and specificity of 87,5%) and PNEF (sensitivity of 65,7% and specificity of
226 85,1%), with area under the ROC curve of 0.99 and 0.92 (95% CI,0.97to1.00 and
227 0.92to0.97, respectively; both $p<0.005$).

228 The predictive values (positive and negative), accuracy, and likelihood ratio
229 values (positive and negative) are in Table 3.

230

231 **Discussion**

232

233 This study examined the utility of PNIF and PNEF measurements as objective
234 precision parameters for the diagnosis of obstruction in patients with allergic rhinitis.
235 Our results show lower PNIF and PNEF values in patients with AR when compared to
236 normal individuals and present reference values in the understanding of the evaluation
237 of nasal obstruction symptoms in rhinitis.

238 Most patients with allergic rhinitis are affected by nasal obstruction⁴⁻¹¹. This
239 symptom is particularly important in patients with persistent allergic rhinitis because
240 even during asymptomatic periods of the disease, mucosal inflammation and nasal
241 congestion may persist to a lesser extent⁴⁻¹¹. However, some patients may find it
242 difficult to reliably identify the presence and the intensity of nasal obstruction due to
243 chronic symptoms or lack of normal breathing. Standardized measures may be an
244 interesting alternative to complement the assessment of these patients making them
245 more aware of nasal obstruction These measures may also be used in epidemiological
246 research⁴⁻¹¹.

247 Teixeira et al.,¹¹ studying PNIF as a tool for assessing nasal patency in 78
248 individuals aged 19 to 67 years without rhinitis and with allergic rhinitis also showed
249 lower PNIF values(114l/min) in individuals with rhinitis compared to individuals

250 without allergic rhinitis(154.3l/min). Thus, reduced nasal flow in patients with
251 allergic rhinitis may be a proxy for nasal obstruction, because the nasal flow of these
252 patients is quantitatively limited in relation to the normal values described^{6,13}. To date
253 no reference values have been described for adult patients with nasal obstruction,
254 therefore the interpretation of these reductions is limited in terms of their clinical
255 impact. However, studies have shown that a 20l/min difference is a clinically
256 significant difference due to the high intra and inter-individual variability of PNIF
257 results¹⁴.

258 The study by Klossek et al.,¹⁵ evaluated the PNIF of normal individuals in the
259 French population and presented normal values below those found in other
260 countries^{13,16} and in our comparison group. However, it is important to consider the
261 difficulty in establishing standardized PNIF measurements, as ethnic factors as well as
262 participants' individual characteristics such as height, age and gender may influence
263 the measurement¹⁵. In a recent study¹⁷, unilateral PNIF was evaluated and normal
264 values for adults were presented with values similar to those already described in the
265 literature¹⁷, showing a positive correlation for gender, height and inverse correlation
266 with age. However, when considering unilateral PNIF and PEF, only height was a
267 significant variable¹⁷.

268 Reference values of the PNEF for the adult population are not widely reported
269 in the literature¹⁸. Values around 260l/min have been reported as possible normality,
270 although there is no range of altered values expected for individuals with Allergic
271 Rhinitis¹⁹. Therefore, this hinders the ability to predict PNEF results in patients with
272 AR and without rhinitis.

273 Our group previously demonstrated a strong positive correlation between
274 PNIF and PNEF(c.c=0.74). However, despite this correlation, PNEF had little
275 explanatory capacity($R^2=0.551$) over PNIF. And therefore, it would not be
276 recommended to replace the PNIF measures with the PNEF measure only¹⁹.

277 Some authors have suggested whenever possible the association of objective
278 measures to better evaluate the obstruction symptom in allergic rhinitis^{7,20}. PNIF has
279 often been studied in association with PEF, as reduced PNIF values may express
280 reduced ventilatory capacity rather than nasal obstruction²¹.

281 Historically PNIF has been successfully used for drug evaluation in the
282 treatment of allergic rhinitis in adults, young people and children²². Part of the studies
283 show that PNIF increases with the improvement of nasal obstruction symptom^{1,23}.

284 However, due to the complexity of subjective perception, the correlation between
285 PNIF and nasal symptoms has been questioned by several studies^{7,20}.

286 Recently, there has been an attempt to further investigate PNIF and PNEF as a
287 diagnostic tool for clinical practice, however these procedures have usually been
288 studied separately and there is no consensual way of correlating them²⁴. In our study,
289 we further tested the ability of PNIF and PNEF measurements to predict nasal
290 obstruction symptoms through the performance of the ROC curve for PNIF and
291 PNEF. Both evaluative methods performed well in identifying the presence of rhinitis,
292 as indicated by the area under the curve (AUC) for PNIF (AUC=0.99) and for PNEF
293 (AUC=0.92). The data also showed that PNIF is more sensitive in identifying the
294 presence of rhinitis, while PNEF performs better in identifying negative conditions for
295 allergic rhinitis. In the same manner, positive predictive values indicate that PNIF
296 showed lower performance, since among patients with altered PNIF, the probability
297 of rhinitis was 73%, compared to 84.8% for PNEF. However, the inverse occurs with
298 the analysis of negative predictive values, since PNIF has a higher value (NPV=97.8)
299 than PNEF (NPV=87.7). When analyzed globally, in terms of accuracy, which
300 indicates the proportion of correct answers in relation to all possible outcomes, PNEF
301 presents better overall performance (PNIF=81.7 and PNEF=86.3).

302 The same degree of specificity found in our study was also observed by
303 Schwanz-Starling et al.,⁹ when evaluating the reproducibility of the PNIF
304 measurement in patients with rhinitis. The authors demonstrated that PNIF
305 measurements may reflect the severity of nasal rhinitis symptoms in young adults.
306 The use of PNIF has also been evaluated in patients undergoing tonsil removal
307 surgery. Bathala and Eccles²⁵ demonstrated that 72% of patients had a 22% increase
308 in PNIF values after tonsillectomy.

309 A recent study evaluated PNIF after patients underwent functional
310 rhinoseptoplasty. In this study, Fuller et al.,²⁴ demonstrated that the nasal
311 obstruction(Nose) scale score is lower in those patients with higher nasal PNIF
312 values, which indicates a convergence between the two methods regarding the
313 improvement of airway patency. Despite this, the data revealed a weak correlation
314 between the two measures. Thus, these authors consider the use of PNIF as a
315 diagnostic measure, although they emphasize the possibility of this tool as a follow-up
316 measure in the prognosis of patients undergoing septum correction surgery.

317 A possible limitation of the study was not to carry out a follow up of these

318 patients according to the clinical response to treatment to evaluate the change of
319 parameter settings. That way, all assessments could have been repeated after 15 days
320 to make sure of reproducibility. Even so, this research has strengths as it is a pioneer
321 in the analysis of symptom scores, visual analog scale, PNIF and PFEF.

322

323 **Conclusions**

324

325 Our findings reinforce the importance of PNIF and PNEF measures to complement
326 the more refined assessment of patients' symptoms. The performance of the PNEF
327 ROC curve gives us about this objective evaluation parameter, as this measure can be
328 a valuable tool in screening patients who seek to exclude rhinitis symptoms and to
329 complement the PNIF measurement.

330

331 **Acknowledgements**

332

333 We appreciate the partnership with London South Bank University, Pernambuco
334 University and Federal Pernambuco University.

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352 **REFERENCES**

- 353 1. Baraniuk JN. Subjective Nasal Fullness and Objective Congestion. Proc Am
354 Thorac Soc 2011;8:62-69. <https://doi.org/10.1513/pats.201006-042RN>
- 355 2. Krouse J, Lund V, Fokkens W, et al. Diagnostic strategies in nasal congestion. Int J
356 Gen Med 2010;8:59-67. <https://doi.org/10.2147/IJGM.S8084>
- 357 3. Stull DE, Meltzer EO, Krouse JH, et al. The Congestion Quantifier Five-Item Test
358 for Nasal Congestion: Refinement of the Congestion Quantifier Seven-Item Test. Am
359 J Rhinol Allergy 2010;24:34-38. <https://doi.org/10.2500/ajra.2010.24.3394>
- 360 4. André RF, Vuyk HD, Ahmed A, et al. Correlation between subjective and objective
361 evaluation of the nasal airway. A systematic review of the highest level of evidence.
362 Clin Otolaryngol 2009;34:518-525. <https://doi.org/10.1111/j.1749-4486.2009.02042.x>
- 363 5. Jones A, Viani L, Phillips D, et al. The objective assessment of nasal patency. Clin
364 Otolaryngol Allied Sci 1991;16:206-211. <https://doi.org/10.1111/j.1365-2273.1991.tb01978.x>
- 366 6. Ottaviano G, Fokkens WJ. Measurements of nasal airflow and patency: a critical
367 review with emphasis on the use of peak nasal inspiratory flow in daily practice.
368 Allergy 2016;71:162-174. <https://doi.org/10.1111/all.12778>
- 369 7. Chaaban M, Corey JP. Assessing Nasal Air Flow: Options and Utility. Proc Am
370 Thorac Soc 2011;8:70-78. <https://doi.org/10.1513/pats.201005-034RN>
- 371 8. Gomes DL, Camargos PAM, Ibiapina CC, et al. Nasal peak inspiratory flow and
372 clinical score in children and adolescents with allergic rhinitis. Rhinology
373 2008;46:276-280.
- 374 9. Starling-Schwanz R, Peake HL, Salome CM, et al. Repeatability of peak nasal
375 inspiratory flow measurements and utility for assessing the severity of rhinitis.
376 Allergy 2005;60:795-800. <https://doi.org/10.1111/j.1398-9995.2005.00779.x>
- 377 10. Van SE, Ingels KJAO, Jansen AH, et al. Evidence-based recommendations
378 regarding the differential diagnosis and assessment of nasal congestion: using the new
379 GRADE system. Allergy 2008;63:820-833. <https://doi.org/10.1111/j.1398-9995.2008.01729.x>
- 381 11. Teixeira RUF, Zappelini CEM, Oliveira LG, et al. Correlation Between the Peak
382 Nasal Inspiratory Flow and the Visual Analogue Scale Before and After Using a
383 Nasal Decongestant. Arq Int Otorrinolaringol 2011;15:156-
384 162. <https://doi.org/10.1590/S1809-48722011000200006>
- 385 12. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on

386 Asthma (ARIA) 2008*. *Allergy* 2008;63:8-160. [https://doi.org/10.1111/j.1398-](https://doi.org/10.1111/j.1398-9995.2007.01620.x)
387 9995.2007.01620.x

388 13. Ottaviano G, Scadding GK, Iacono V, et al. Peak nasal inspiratory flow and peak
389 expiratory flow. Upright and sitting values in an adult population. *Rhinology*
390 2016;54:160-163. <https://doi.org/10.4193/Rhin15.180>

391 14. Timperley D, Srubisky A, Stow N, et al. Minimal clinically important differences
392 in nasal peak inspiratory flow. *Rhinology* 2011;49:37-40.
393 <https://doi.org/10.4193/Rhino10.097>

394 15. Klossek J-M. PNIF measurement in a healthy French population. A prospective
395 study about 234 patients. *Rhinology* 2009;47. <https://doi.org/10.4193/Rhin08.083>

396 16. Papachristou A, Bourli E, Aivazi D, et al. Normal peak nasal inspiratory flow rate
397 values in Greek children and adolescents. *Hippokratia* 2008;12:94-97.
398 <https://doi.org/18923655>

399 17. Ottaviano G, Scadding GK, Scarpa B, et al. Unilateral peak nasal inspiratory flow,
400 normal values in adult population. *Rhinology* 2012;50:386-392.
401 <https://doi.org/10.4193/Rhino12.071>

402 18. Hellgren J, Jarlstedt J, Dimberg L, et al. A study of some current methods for
403 assessment of nasal histamine reactivity. *Clin Otolaryngol Allied Sci* 1997;22:536-
404 541. <https://doi.org/10.1046/j.1365-2273.1997.00073.x>

405 19. Oliveira GM, Rizzo JA, Camargos PAM, et al. Are measurements of peak nasal
406 flow useful for evaluating nasal obstruction in patients with allergic rhinitis?
407 *Rhinology* 2015;53:160-166. <https://doi.org/10.4193/Rhin14.048>

408 20. Lam DJ, James KT, Weaver EM. Comparison of Anatomic, Physiological, and
409 Subjective Measures of the Nasal Airway. *Am J Rhinol* 2006;20:463-470.
410 <https://doi.org/10.2500/ajr.2006.20.2940>

411 21. Ottaviano G, Lund VJ, Coles S, et al. Does peak nasal inspiratory flow relate to
412 peak expiratory flow? *Rhinology* 2008;46:200-203.

413 22. Bermüller C, Kirsche H, Rettinger G, et al. Diagnostic Accuracy of Peak Nasal
414 Inspiratory Flow and Rhinomanometry in Functional Rhinosurgery. *Laryngoscope*
415 2008;118:605-610. <https://doi.org/10.1097/MLG.0b013e318161e56b>

416 23. Wilson AM, Haggart K, Sims EJ, et al. Effects of fexofenadine and desloratadine
417 on subjective and objective measures of nasal congestion in seasonal allergic rhinitis.
418 *Clin Exp Allergy* 2002;32:1504-1509. [https://doi.org/10.1046/j.1365-](https://doi.org/10.1046/j.1365-2745.2002.01509.x)
419 2745.2002.01509.x

420 24. Fuller JC, Bernstein CH, Levesque PA, et al. Peak Nasal Inspiratory Flow as an
421 Objective Measure of Nasal Obstruction and Functional Septorhinoplasty Outcomes.
422 JAMA Facial Plast Surg 2018;20:175-176.
423 <https://doi.org/10.1001/jamafacial.2017.1775>
424 25. Bathala S, Eccles R. Assessment of upper airway obstruction by measuring peak
425 oral and nasal inspiratory flow. J Laryngol Otol 2015;129:473-477.
426 <https://doi.org/10.1017/S0022215115000523>

427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453

480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516

Table 2. Peak nasal inspiratory flow and Peak nasal expiratory flow by sex. Peak nasal inspiratory flow and Peak nasal expiratory flow by sex

| Variable | SEX | Rhinitis | Without rhinitis |
|-----------------|----------------|---------------------------|----------------------------|
| PNIF | General | 65.94±18.32 ^a | 130.73±26.64 ^a |
| | Male | 70.0±15.95 ^b | 145.0±29.75 ^{b g} |
| | Female | 65.0±18.84 ^c | 120.5±18.63 ^{c g} |
| PNEF | General | 108.36±56.87 ^d | 212.54±48.88 ^d |
| | Male | 130.8±71.54 ^e | 232.9±50.47 ^{e h} |
| | Female | 103.2±52.39 ^f | 198.0±42.62 ^{f h} |

Data were expressed mean ± standard deviation. Same letters indicated statistically significant differences between pairs, considering $p \leq 0,01$ from test *t* onwards for independent samples.

517
518
519
520
521
522
523

524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554

Table 3. Sensitivity, specificity, predictive values and likelihood of PNIF and PNEF.
Sensitivity, specificity, predictive values and likelihood of PNIF and PNEF.

| | PNIF (Cutoff point = 115) | PNEF (Cutoff point = 165) |
|---------------------------------|--|--|
| Sensitivity | 98,4 | 87,5 |
| Specificity | 65,7 | 85,1 |
| positive predictive value (VPP) | 73,3 | 84,8 |
| negative predictive value (VPN) | 97,8 | 87,7 |
| Accuracy | 81,7 | 86,3 |

555

556 **Figure legends**

557

558

559

560 **Figure 1.** Area under the curve from Peak nasal inspiratory flow (PNIF - A) and Peak
561 nasal expiratory (PNEF-B). AUC = Area under the curve; CI = confidence interval